PUMA Trial Challenges Standard Heart Surgery Monitoring with $3.7M Study Comparing Invasive Devices
核心洞察
The PUMA trial, led by Monash University's Victorian Heart Institute (搜索), will compare pulmonary artery catheters and central venous catheters in 2,000 heart surgery patients to determine optimal monitoring approaches.
Researchers aim to reduce unnecessary treatments, shorten ICU stays, and cut healthcare costs by potentially adopting less invasive monitoring methods for the 20,000 Australians undergoing open heart surgery annually.
The study addresses decades of international controversy around pulmonary artery catheters, which have been de-adopted in other high-risk patient groups due to lack of proven benefits.
A groundbreaking clinical trial led by Monash University's Victorian Heart Institute (搜索) is set to challenge decades of standard practice in cardiac surgery monitoring, potentially transforming care for more than 20,000 Australians who undergo open heart surgery each year. The PUMA trial has received $3.7 million in funding from the Medical Research Future Fund to compare two monitoring approaches and determine whether current invasive practices truly benefit patients.
Patient-Centered Trial Design
The 2,000-patient study represents a unique collaboration between researchers and patients, with cardiac surgery survivor Paige Druce serving as a lived-experience investigator who has shaped the trial's priorities from its earliest phases. "It is important to feel confident that every procedure is truly necessary," Druce said. "Co-designing clinical trials with people who have lived experience is important because it helps to make sure the research focuses on things that matter to the people it's meant to help."
Druce, who has undergone cardiac surgery twice, emphasized that patient involvement "ensures that the research is done in a way that feels fair and respectful to those taking part."
Comparing Monitoring Technologies
The PUMA trial will directly compare the commonly used pulmonary artery catheter (PAC) against the central venous catheter (CVC), a less invasive alternative that researchers believe could deliver multiple benefits. The study aims to determine whether the simpler CVC approach can reduce unnecessary treatments, shorten intensive care unit stays, decrease healthcare costs, and significantly reduce the environmental footprint of intensive care by 2030.
"Pulmonary artery catheters provide important information about heart function," explained Associate Professor Lachlan Miles, PUMA co-investigator and Head of Research in the Department of Anaesthesia at Austin Health. "Unfortunately, they are not without risk, and could even trigger unnecessary treatments, increase complications, and prolong hospital admissions."
Addressing International Controversy
Lead investigator Dr. Luke Perry, Head of Anaesthetic Research at the Victorian Heart Institute (搜索), noted that the cardiac surgery field has lagged behind other medical specialties in evaluating the effectiveness of pulmonary artery catheters. "These invasive devices have been broadly de-adopted in other high-risk patient groups after large clinical trials due to sepsis, acute respiratory distress syndrome, and use in non-cardiac surgery failing to show a benefit to patients," Perry said.
The PUMA trial seeks to "resolve decades of international controversy around the role of pulmonary artery catheters in contemporary practice, paving the way for high-value care that could reduce major complications and get patients home to their families sooner."
Study Implementation and Timeline
The trial has received endorsement from the Australia and New Zealand College of Anaesthetists Clinical Trials Network and will begin patient recruitment in Australia and internationally in 2026. The study's design reflects a commitment to modernizing cardiac surgery practices based on robust evidence rather than historical precedent.
The research team expects the findings to have significant implications for cardiac surgery protocols worldwide, potentially establishing new standards for perioperative monitoring that prioritize patient safety while reducing healthcare system burden.